

Attorney Docket No.: 6573.204-US  
Kaarsholm et al.  
Application No.: 10/825,995 Filed: April 16, 2004  
Via Facsimile No.: 571-273-8300

RECEIVED  
CENTRAL FAX CENTER  
OCT 26 2006

Attorney Docket No.: 6573.204-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Kaarsholm et al.

Confirmation No.: 9239

Application No.: 10/825,995

Group Art Unit: 1654

Filed: April 16, 2004

Examiner: Bradley, Christina

For: Stabilised Insulin Compositions

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

This paper is filed in response to the Office Action mailed June 27, 2006, having a shortened statutory period for reply set to expire July 27, 2006, subject to extensions of time under 37 C.F.R. §1.136(a). A petition for a three (3) month extension of time to increase the period for reply from July 27, 2006, to October 27, 2006, is enclosed herewith to permit timely filing of this response.

The Examiner states that claims numbered 1-220 are pending in the application and claims 1-220 are subject to a restriction and/or election requirement.

The Examiner has required a restriction in this application for examination purposes to one of the following inventions:

Group I. Claims 2-57, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of




Attorney Docket No.: 6573.204-US

Kaarsholm et al.


Application No.: 10/825,995 Filed: April 16, 2004

Via Facsimile No.: 571-273-8300


Group II. Claims 2-57, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of




Group III. Claims 2-57, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Group IV. Claims 58-104, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Group V. Claims 58-104, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of




Group VI. Claims 58-104, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of

Attorney Docket No.: 6573.204-US


Kaarsholm et al.

Application No.: 10/825,995 Filed: April 16, 2004


Via Facsimile No.: 571-273-8300




Group VII. Claims 58-104, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of




Group VIII. Claims 105-126, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Group IX. Claims 105-126, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Group X. Claims 105-126, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of




Attorney Docket No.: 6573.204-US

Kaarsholm et al.


Application No.: 10/825,995 Filed: April 16, 2004

Via Facsimile No.: 571-273-8300


Group XI. Claims 127-170, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Group XII. Claims 171-186, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Group XIII. Claims 187-205, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Group XIV. Claim 219, drawn to a method for stabilizing insulin.

Group XV. Claim 220, drawn to a method for treating diabetes.

Claims 1 and 205-218 are linking claims that link inventions I-XIII.

In response to the restriction requirement, Applicant hereby elects, for examination purposes, the invention of:

Group XI. Claims 127-170, drawn to a pharmaceutical composition comprising insulin and a zinc-binding ligand of



Attorney Docket No.: 6573.204-US


Kaarsholm et al.

Application No.: 10/825,995 Filed: April 16, 2004

Via Facsimile No.: 571-273-8300

Applicant additionally elects a single species, for examination purposes only, disclosed in Example 575, found on page 243, lines 1-23, of the specification as originally filed:

5-(3-Phenoxymethyl)-phenyl)-tetrazole



Applicant hereby reserves the right to file continuing or divisional applications directed to the nonelected and/or cancelled subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: October 26, 2006

Rosemarie R. Wilk-Orescan  
Registration Number 45,220  
Novo Nordisk Inc.  
100 College Road West  
Princeton, NJ 08540  
609-987-5969

Customer Number

23650

PATENT TRADEMARK OFFICE